Day: July 2, 2021

Sponsorship Opportunity for PsyTech Summit provides robust environment for awareness alongside some of the biggest names in the psychedelic industry MIAMI, July 02, 2021 (GLOBE NEWSWIRE) — Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today it will be one of four sponsors at PsyTech, an upcoming complimentary Psychedelic Industry summit taking place virtually on July 19-20 for investors and interested individuals. The third annual PsyTech Summit will cover the most heated topics in the psychedelic sector today, like ketamine-assisted therapy, microdosing, promising new innovations in developmental phases, and much more. “Sponsoring the PsyTech Summit is a great opportunity for Ehave and its shareholders as we roll out our KetaDASH platform...

Virtual Conference boasts some of the biggest names in the psychedelic industry MIAMI, July 02, 2021 (GLOBE NEWSWIRE) — Mycotopia Therapies, Inc., (OTC Pink: TPIA) (the “Company”) announced today an upcoming complimentary Psychedelic Industry summit will take place virtually on July 19-20 for investors and interested individuals. The third annual Psytech Summit, where research and industry meet, is produced by PsyTech Inc., a leading source of education, clinical care and clinical tools for the fast-growing psychedelic medical sector. The summit will be a spirited, global discussion focused on today’s most impactful psychedelic therapies, most promising research, and their burgeoning commercial climate through a variety of panels, breakout sessions, and Q&A opportunities with experts. This year’s summit will feature two levels...

Integrity Health Corporation CEO Nelson Grist Announces Company’s New Mission PHOENIX, AZ, July 02, 2021 (GLOBE NEWSWIRE) — via NewMediaWire – Integrity Health Corporation (OTC Pink: FTEG) CEO Nelson Grist is pleased to announce that the Company (www.integrityhealthcorp.com) has a new Mission as a Health Care Company, not just a developer and seller of CBD products. Nelson Grist, CEO of Integrity Health Corporation, said, “The Company’s mission is to: Disrupt the normalcy of traditional Western medicine by making patients more aware they can achieve a healthier, pain-free, longer life through the highest quality products and services designed and dispensed by Integrity Health professionals!” The next step for Integrity Health is to finalize the acquisition of the MedSpa Point Lumineux in Sarasota, Florida from Medical Aesthetics...

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, July 02, 2021 (GLOBE NEWSWIRE) — FIREWEED ZINC LTD. (“Fireweed” or the “Company”) (TSXV: FWZ) is pleased to announce closing of its non-brokered private placement (the “Financing”) announced June 14, 2021 for gross proceeds of CAD$4,503,427 consisting of 5,003,808 flow-through common shares of the Company (“Flow-Through Shares”) at a price of CAD$0.90 per share. The Financing was over-subscribed due to increased demand. The proceeds from the Financing will be used for exploration and development of the Company’s Macmillan Pass Project in Yukon, Canada. Specifically, the Company will incur Canadian Exploration Expenses (“CEE”), which will qualify as “flow-through mining expenditures” under the Income Tax...

SCOTTSDALE, Ariz., July 02, 2021 (GLOBE NEWSWIRE) — AMMO, Inc. (Nasdaq: POWW) (“AMMO” or the “Company”), a premier American ammunition and munition components manufacturer and technology leader, is pleased to provide a link to the transcript and summary excerpts of the Q&A session from the Company’s Fiscal 2021 Earnings call held on June 29, 2021. Replay: https://spaces.hightail.com/receive/hFa3FRFAvO Fiscal 2022 is positioned to be transformative in AMMO’s opinion, with revenue and earnings per share increasing significantly as the Company continues to deploy resources to solidify and enhance 2021’s trajectory through this Fiscal Year. EXCERPTSQ&A session: Matthew Koranda Got it. Okay. Maybe one more from me, and then I’ll turn it over to take turns here. But just in terms of GunBroker, now that it’s been...

Westport, CT, July 02, 2021 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced pricing of its previously announced underwritten public offering of 2,500,000 shares of its common stock, $0.001 par value per share, at a price to the public of $4.00 per share. The gross proceeds to BioSig from this offering are expected to be approximately $10 million, or approximately $11.5 million if the underwriter exercises its 30-day option to purchase an additional 15% of the number of shares of common stock offered in the public offering in full, before deducting the underwriting discounts and commissions...

BEVERLY, Mass., July 02, 2021 (GLOBE NEWSWIRE) — LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, today announced it continues to systematically advance the MiQLab™ System to meet the Food and Drug Administration (FDA) criteria for Emergency Use Authorization (EUA). The MiQLab System is a first of its kind, point of care diagnostic testing technology. The FDA EUA process requires novel diagnostic devices to undergo a substantial amount of complex design control and testing. All functions for critical system operation must be validated and submitted as part of the process. Dr. Jack Regan, LexaGene’s Founder and CEO, stated, “The MiQLab systems we’ve sold into veterinary diagnostics and the biologics manufacturing market...

MONTRÉAL, July 02, 2021 (GLOBE NEWSWIRE) — Bombardier Inc. (“Bombardier” or the “Corporation”) announced today that its cash tender offer previously announced on June 3, 2021 (as amended by the Corporation’s press release dated June 17, 2021 and as further amended by the Corporation’s press release dated June 25, 2021, the “Tender Offer”) to purchase for cash up to US$1,000,000,000 aggregate purchase price (exclusive of Accrued Interest) (the “Aggregate Maximum Purchase Amount”) of three series of its outstanding senior notes (collectively, “Notes”) due 2022 and 2023 as identified in the Offer to Purchase (as defined below), expired at the Expiration Date, 11:59 P.M., New York City time, on July 1, 2021. Capitalized terms used but not defined herein shall have the meanings assigned to such terms in the Offer to Purchase dated June...

Alector and GSK to co-develop progranulin-elevating monoclonal antibodies, AL001 and AL101, for a range of neurodegenerative diseases, including frontotemporal dementia, amyotrophic lateral sclerosis, Parkinson’s disease and Alzheimer’s disease Companies will co-commercialize and share profits in the US; GSK will retain exclusive commercialization rights outside the US Alector will receive $700 million in upfront payments, up to $1.5 billion in potential milestone payments, profit sharing and royalties Alector management to host conference call today at 8:30 a.m. ETSOUTH SAN FRANCISCO, Calif. and LONDON, July 02, 2021 (GLOBE NEWSWIRE) — Alector, Inc. (Nasdaq: ALEC) and GlaxoSmithKline plc (LSE/NYSE: GSK), today announced a strategic global collaboration for the development and commercialization of two clinical-stage, potential...